The high-density fermentation process for producing ultra-high purity NMN (β-Nicotinamide Mononucleotide CAS No.: 1094-61-7) using nicotinamide riboside kinase (NRK) represents a groundbreaking approach in production methodologies. NRK exhibits heightened enzymatic activity, thereby reducing the production costs associated with NRK kinase and improving the catalytic efficiency of NMN synthesis. This advancement effectively addresses the challenge of high catalyst preparation costs in the NMN production process. Achieving a conversion rate as high as 98%, coupled with NMN purity levels reaching up to 99.99%, underscores the efficacy of this innovative method.

    The fermentation process is structured into two distinct stages, facilitating high-density fermentation in recombinant NRK gene-engineered bacteria. This approach not only enhances the cell density of engineered bacteria producing NRK, with cell density reaching a maximum OD600 of 270 and wet cell weight of 300g/L, but also elevates the enzymatic activity of NRK. Consequently, the fermentation broth yields NRK activity exceeding 105U/mL, a testament to the effectiveness and efficiency of this process.

    This breakthrough production method holds immense promise for various applications, particularly in the pharmaceutical and nutraceutical industries. With its ability to produce ultra-high purity NMN at significantly reduced costs, it paves the way for widespread utilization of NMN in medical treatments, dietary supplements, and other health-related products. Furthermore, the scalability and efficiency of this process make it a viable solution for meeting increasing market demands for NMN, thus driving advancements in healthcare and wellness. Continued research and optimization of this method are expected to further enhance its capabilities and broaden its potential applications in the future.